> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-173/
- Published: 2018-04-01T12:00:00.000Z
- Updated: 2026-09-14T23:56:34.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141117

[**Joint Panel to Discuss Celebrex Safety Data**](https://www.fdaweb.com/joint-panel-to-discuss-celebrex-safety-data/)  
*Federal Register* notice: FDA announces a 4/24-25 joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting to discuss Celebrex safety v. ibuprofen or naproxen. 03/30/2018

[**Workshop on Generic Regulatory Science Initiatives**](https://www.fdaweb.com/workshop-on-generic-regulatory-science-initiatives-3/)  
*Federal Register* notice: FDA announces a 5/24 public workshop on “FY 2018 Generic Drug Regulatory Science Initiatives.” 03/30/2018

[**Joint Advisory Panel to Meet on Pain Drug NDA**](https://www.fdaweb.com/joint-advisory-panel-to-meet-on-pain-drug-nda/)  
*Federal Register* notice: FDA announces a 5/22 joint Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee advisory committee meeting. 03/30/2018

[**Revised Draft Guide for Generic Doxycycline Hyclate**](https://www.fdaweb.com/revised-draft-guide-for-generic-doxycycline-hyclate/)  
*Federal Register* notice: FDA makes available a revised draft guidance on generic doxycycline hyclate oral delayed-release tablets, entitled “Product-Specific Guidance for Doxycycline Hyclate.” 03/29/2018

[**New Info Collection Sought for Drug Compounding Guide**](https://www.fdaweb.com/new-info-collection-sought-for-drug-compounding-guide/)  
*Federal Register* notice: FDA seeks OMB approval for a new information collection entitled “Guidance for Industry on Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503B of the Federal Food, Drug, and Cosmetic Act.” 03/29/2018

[**Organization Change to CDER Regulatory Policy Office**](https://www.fdaweb.com/organization-change-to-cder-regulatory-policy-office/)  
*Federal Register* Final Rule; technical amendment: FDA amends its regulations to reflect an organizational change for CDER’s Office of Regulatory Policy. 03/28/2018

[**Gastrointestinal Drugs Advisory Committee Charter Extended**](https://www.fdaweb.com/gastrointestinal-drugs-advisory-committee-charter-extended/)  
*Federal Register* notice: FDA renews for an additional two years the charter for its Gastrointestinal Drugs Advisory Committee. 03/28/2018

[**FDA Joint Panel to Review InfaCare Pharma NDA**](https://www.fdaweb.com/fda-joint-panel-to-review-infacare-pharma-nda/)  
*Federal Register* notice: FDA announces a 5/3 joint Gastrointestinal Drugs Advisory Committee and Pediatric Advisory Committee meeting. 03/28/2018

[**Compounding Committee Seeks Member Nominations**](https://www.fdaweb.com/compounding-committee-seeks-member-nominations/)  
*Federal Register* notice: FDA requests nominations for members to serve on its Pharmacy Compounding Advisory Committee. 03/27/2018